A Phase 2b Randomised, Double-blind, Placebo-controlled, Parallel, Adaptive 2-Stage, Multi-Centre Study to Evaluate the Safety and Efficacy of Oral PTG-100 Induction in Subjects With Moderate to Severe Active Ulcerative Colitis
Phase of Trial: Phase II
Latest Information Update: 08 Oct 2017
At a glance
- Drugs PTG 100 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Protagonist Therapeutics
- 08 Aug 2017 According to a Protagonist Therapeutics media release, the interim analysis is now expected in early 2018; top-line results are still anticipated for the second half of 2018.
- 10 Jun 2017 Biomarkers information updated
- 18 Jan 2017 Planned End Date changed from 1 May 2018 to 1 Jun 2018.